MEDITE Cancer Diagnostics Inc (MDIT):企業の財務・戦略的SWOT分析

GlobalDataが発行した調査報告書(DATA904C2608)
◆英語タイトル:MEDITE Cancer Diagnostics Inc (MDIT) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C2608
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年8月
◆ページ数:42
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥18,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

MEDITE Cancer Diagnostics Inc (MDIT) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

MEDITE Cancer Diagnostics Inc (MEDITE), formerly CytoCore, Inc., specializes in the development, engineering, manufacturing and marketing of premium medical devices and consumables for detection, risk assessment and diagnosis of cancer and related diseases. Its major devices include ultrasonic decalcification instruments, tissue processing instruments, freezing microtome, cryostats, linear staining systems, staining systems, and cytology screening systems. The company’s products find application in processing tissue, cell collection ranging from processing to diagnosis. These devices and consumables are manufactured at is facility in Burgdorf, Germany. The company sells its products through a direct sale force located in Germany, Poland and the US, and also through independent distributors. MEDITE is headquartered in Orlando, Florida, the US.

MEDITE Cancer Diagnostics Inc Key Recent Developments

Nov 15,2017: MEDITE Cancer Diagnostics Appoints Joel Kanter To Its Board As An Independent Director
Nov 08,2017: MEDITE Cancer Diagnostics Reports Appointments of New Chairman of the Board and Chief Executive Officer
Aug 14,2017: MEDITE Cancer Diagnostics Reports 2017 Second Quarter and First Six Month Financial Results
Jul 27,2017: MEDITE Cancer Diagnostics to Launch SureCyte C1 Stain Globally at the 29th European Congress of Pathology
May 10,2017: MEDITE Cancer Diagnostics Announces Reorganization of Germany Operations

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Section 1 – About the Company 5
MEDITE Cancer Diagnostics Inc – Key Facts 5
MEDITE Cancer Diagnostics Inc – Key Employees 6
MEDITE Cancer Diagnostics Inc – Key Employee Biographies 7
MEDITE Cancer Diagnostics Inc – Major Products and Services 8
MEDITE Cancer Diagnostics Inc – History 9
MEDITE Cancer Diagnostics Inc – Locations And Subsidiaries 11
Head Office 11
Other Locations & Subsidiaries 11
Section 2 – Company Analysis 12
Company Overview 12
MEDITE Cancer Diagnostics Inc – Business Description 13
MEDITE Cancer Diagnostics Inc – SWOT Analysis 14
SWOT Analysis – Overview 14
MEDITE Cancer Diagnostics Inc – Strengths 14
MEDITE Cancer Diagnostics Inc – Weaknesses 15
MEDITE Cancer Diagnostics Inc – Opportunities 16
MEDITE Cancer Diagnostics Inc – Threats 17
MEDITE Cancer Diagnostics Inc – Key Competitors 18
Section 3 – Company Financial Ratios 19
Financial Ratios – Capital Market Ratios 19
Financial Ratios – Annual Ratios 20
Performance Chart 23
Financial Performance 23
Financial Ratios – Interim Ratios 24
Financial Ratios – Ratio Charts 25
Section 4 – Company’s Lifesciences Financial Deals and Alliances 26
MEDITE Cancer Diagnostics Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 26
MEDITE Cancer Diagnostics Inc, Medical Equipment, Deals By Type, 2012 to YTD 2018 27
MEDITE Cancer Diagnostics Inc, Recent Deals Summary 28
Section 5 – Company’s Recent Developments 29
Nov 15, 2017: MEDITE Cancer Diagnostics Appoints Joel Kanter To Its Board As An Independent Director 29
Nov 08, 2017: MEDITE Cancer Diagnostics Reports Appointments of New Chairman of the Board and Chief Executive Officer 30
Aug 14, 2017: MEDITE Cancer Diagnostics Reports 2017 Second Quarter and First Six Month Financial Results 31
Jul 27, 2017: MEDITE Cancer Diagnostics to Launch SureCyte C1 Stain Globally at the 29th European Congress of Pathology 33
May 10, 2017: MEDITE Cancer Diagnostics Announces Reorganization of Germany Operations 34
Apr 28, 2017: MEDITE Cancer Diagnostics Announces Reorganization of Germany Operations 35
Apr 27, 2017: MEDITE Cancer Diagnostics Appoints Susan Weisman as Chief Financial Officer 36
Mar 07, 2017: MEDITE Cancer Diagnostics Appoints Eric M. Goehausen to Board of Directors 37
Section 6 – Appendix 38
Methodology 38
Ratio Definitions 38
About GlobalData 42
Contact Us 42
Disclaimer 42

List of Tables
MEDITE Cancer Diagnostics Inc, Key Facts 5
MEDITE Cancer Diagnostics Inc, Key Employees 6
MEDITE Cancer Diagnostics Inc, Key Employee Biographies 7
MEDITE Cancer Diagnostics Inc, Major Products and Services 8
MEDITE Cancer Diagnostics Inc, History 9
MEDITE Cancer Diagnostics Inc, Subsidiaries 11
MEDITE Cancer Diagnostics Inc, Key Competitors 18
MEDITE Cancer Diagnostics Inc, Ratios based on current share price 19
MEDITE Cancer Diagnostics Inc, Annual Ratios 20
MEDITE Cancer Diagnostics Inc, Annual Ratios (Cont...1) 21
MEDITE Cancer Diagnostics Inc, Annual Ratios (Cont...2) 22
MEDITE Cancer Diagnostics Inc, Interim Ratios 24
MEDITE Cancer Diagnostics Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 26
MEDITE Cancer Diagnostics Inc, Medical Equipment, Deals By Type, 2012 to YTD 2018 27
MEDITE Cancer Diagnostics Inc, Recent Deals Summary 28
Currency Codes 38
Capital Market Ratios 38
Equity Ratios 39
Profitability Ratios 39
Cost Ratios 40
Liquidity Ratios 40
Leverage Ratios 41
Efficiency Ratios 41

List of Figures
MEDITE Cancer Diagnostics Inc, Performance Chart (2013 - 2017) 23
MEDITE Cancer Diagnostics Inc, Ratio Charts 25
MEDITE Cancer Diagnostics Inc, Medical Equipment, Deals By Year, 2012 to YTD 2018 26
MEDITE Cancer Diagnostics Inc, Medical Equipment, Deals by Type, 2012 to YTD 2018 27

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ MEDITE Cancer Diagnostics Inc (MDIT):企業の財務・戦略的SWOT分析(MEDITE Cancer Diagnostics Inc (MDIT) - Financial and Strategic SWOT Analysis Review)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆